First Patient Dosed in Sleep Apnea Pill Second Phase 2 Clinical Trial
A total of 30 participants will be enrolled. Each participant will receive two different dose levels of AD109, and placebo, at bedtime.
A total of 30 participants will be enrolled. Each participant will receive two different dose levels of AD109, and placebo, at bedtime.
"There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person's daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time."
Jazz Pharmaceuticals plc announced that the first patient has been enrolled in a Phase 3 clinical study evaluating JZP-258, an investigational oxybate product candidate with 90% less sodium content than Xyrem (sodium oxybate)...
IMB-115 is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor.
Read MoreThe Breakthrough Therapy designation for AXS-12 was supported by the positive results from the Phase 2 CONCERT study.
Read More“We are at a pivotal point in Avadel’s transformation, as we recently completed our pre-NDA meeting with the FDA and are currently focused on completing our NDA submission and filing for FT218.”
Read MoreIdorsia Ltd reports positive results from the first pivotal Phase 3 study investigating 25 and 50 mg doses of its dual orexin receptor antagonist, daridorexant, in adult and elderly patients with insomnia.
Read MoreHETLIOZ (tasimelteon) improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome in a placebo-controlled clinical study.
Read MoreWhen on opioids, people with sleep apnea are likely to have more breathing pauses than those who are not medicated.
Read MoreThe study will enroll about 250 patients at most of the North American clinical trial sites that participated in the REST-ON study.
Read MoreThe sale of the sterile injectable drug portfolio is a significant milestone for the company, as it reflects a commitment to strategically focus on advancing FT218.
Read MoreResearchers demonstrated that the neurotransmitter serotonin plays a critical role in rousing the brain from sleep when CO2 levels rise.
Read MoreAn investigational CPAP alternative that uses tetanus toxin molecules to potentially treat sleep-disordered breathing is being unveiled at a global biotech innovation event this week.
Read MoreIts findings suggest that ZTL-101 cannabis treatment is safe and effective for chronic insomnia.
Read MoreTherapix Biosciences has closed a joint venture transaction for collaboration in the field of developing pharmaceuticals for a sleep-related indication.
Read MoreTokyo-based Sosei Group Corp has made further progress with its orexin program, which is being developed in conjunction with its spin-off companies Orexia Ltd and Inexia Ltd.
Read MoreRespireRx Pharmaceuticals Inc, which is developing dronabinol for the treatment of obstructive sleep apnea, announces that Timothy Jones has joined as its president and CEO.
Read More